USRE35770E - Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them - Google Patents
Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- USRE35770E USRE35770E US08/574,761 US57476195A USRE35770E US RE35770 E USRE35770 E US RE35770E US 57476195 A US57476195 A US 57476195A US RE35770 E USRE35770 E US RE35770E
- Authority
- US
- United States
- Prior art keywords
- sulfate
- glucosamine
- oligosaccharide
- activity
- yin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 98
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 96
- 230000000694 effects Effects 0.000 title claims description 41
- 230000001858 anti-Xa Effects 0.000 title claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229920000669 heparin Polymers 0.000 claims abstract description 45
- 229960002897 heparin Drugs 0.000 claims abstract description 45
- 230000002785 anti-thrombosis Effects 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 13
- 150000001720 carbohydrates Chemical group 0.000 claims description 11
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 9
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 6
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000001371 heparinic effect Effects 0.000 abstract description 8
- 229940127217 antithrombotic drug Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 58
- 238000000034 method Methods 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 108090000935 Antithrombin III Proteins 0.000 description 21
- 238000010828 elution Methods 0.000 description 20
- 108010022901 Heparin Lyase Proteins 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 229920005654 Sephadex Polymers 0.000 description 16
- 239000012507 Sephadex™ Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 16
- 238000002523 gelfiltration Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 102100022977 Antithrombin-III Human genes 0.000 description 15
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000000717 retained effect Effects 0.000 description 10
- 150000004044 tetrasaccharides Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 9
- 229920002684 Sepharose Polymers 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical group OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 229960005348 antithrombin iii Drugs 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 102000004411 Antithrombin III Human genes 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 150000002016 disaccharides Chemical class 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 5
- 238000000424 optical density measurement Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000605114 Pedobacter heparinus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- KZWHEHSUEBTKJM-SLPGGIOYSA-N [(2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]sulfamic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NS(O)(=O)=O KZWHEHSUEBTKJM-SLPGGIOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000002565 heparin fraction Substances 0.000 description 2
- 150000008273 hexosamines Chemical class 0.000 description 2
- 230000003027 hypercoagulation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004816 paper chromatography Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical group O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical group OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 240000003834 Triticum spelta Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- GRLOBEDQFXAWHW-GASJEMHNSA-N [(3R,4R,5S,6R)-2-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]sulfamic acid Chemical group S(=O)(=O)(O)N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O)CO)N GRLOBEDQFXAWHW-GASJEMHNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- HIGRAKVNKLCVCA-UHFFFAOYSA-N alumine Chemical compound C1=CC=[Al]C=C1 HIGRAKVNKLCVCA-UHFFFAOYSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical group N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
- G01N2333/8128—Antithrombin III
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Definitions
- the invention relates to oligosaccharidic fractions and to oligosaccharides having biological properties, particularly the ability of more specifically controlling some steps of the blood coagulation.
- the invention also relates to processes for obtaining said products and to the use of said products as active principles in drugs.
- the invention relates more particularly to oligosaccharides having a highly selective activity against activated factor X or factor Xa of blood i.e. a strong antithrombotic activity, while avoiding the risk of hemorrhage for the patient, as well as to oligosaccharidic fractions containing such oligosaccharides (the term "oligosaccharidic fractions" is used in the specification and the claims to designate a relatively homogeneous mixture of oligosaccharidic fragments or chains having a variable number of saccharidic moieties).
- the inventors have been led to investigate the biologically active oligosaccharidic fractions and the oligosaccharides themselves, such as obtained from heparin.
- heparin is used in the specification and the claims in its broadest sense, in order to designate either a commercial heparin of pharmaceutical grade or a crude heparin such as obtained by extraction from biological material, particularly from mammalian tissue.
- heparin is an heterogeneous polysaccharide with respect to the composition of its oligosaccharidic chains as well as to the molecular weight thereof.
- heparin mainly contains 2-O-sulfate-L-iduronic acid and N-sulfate-D glucosamine (6-O-sulfated or not) and to a lesser extent D-glucuronic acid, L-iduronic acid and N-acetyl-D-glucosamine (6-O-sulfated or not) moieties.
- heparin produces its anticoagulant activity by potentiating the inhibitory effect of antithrombin III ( ⁇ ATIII) which is a plasma protein against the successive enzymatic reactions of the coagulation cascades.
- ⁇ ATIII antithrombin III
- heparin is able to simultaneously depress a large number of the coagulation factors participating in the creation and the unkeeping of different forms of hypercoagulability, its activity does not appear specific but general.
- oligosaccharides are more satisfactory than heparin with regard to the specificity of their activity. They are more particularly capable of enhancing the specific activity of ATIII with respect to a smaller number of coagulation factors, more especially with respect to factor Xa.
- the Yin-Wessler activity is more specifically representative of the capability of the active fractions to potentiate the inhibition of the activated factors Xa of blood by AT III in the corresponding test and the UPS titer is representative of the capability of the active fractions to inhibit the global coagulation of blood or plasma.
- the Yin-Wessler titer is measured by the test described by these authors in J. Lab. Clin. Med. 1976,81,298-300, and the U.S.P. titer is measured by the test which is described in the "Pharmacopea of the United States of America", XIX, pp. 229-230 (see also the second supplement U.S.P.--NF, p, 62 and the fourth supplement U.S.P.--NF p. 90 respectively entitled "Drug Substances" and "Dosage Forms".
- the desired anti-Xa specific activity was found in the short oligosaccharidic chains, i.e. containing no more than 8 saccharidic moieties, which can be isolated from the depolymerization mixtures by resorting to certain purification steps, carried out under specified conditions.
- saccharide is used in the specification and the claims to designate monosaccharides contained in the heparinic chains.
- the inventors have found that the anti-Xa activity of said fractions and of the oligosaccharides, such as expressed in Yin-Wessler units, was significant of an antithrombotic activity in vivo.
- Such drugs are advantageously useful for antithrombotic treatment without haemorrhage risks.
- Said oligosaccharidic fractions are of the type obtainable by a process which comprises the steps of
- heparin or heparinic fractions possessing anticoagulant activity and having chains with molecular weights ranging from about 2000 to about 50000, with an agent capable of depolymerizing or fragmenting the heparinic chains, the conditions used for carrying out that step being adjusted so as to obtain a depolymerization mixture which contains oligosaccharidic fragments or chains, constituted by no more than 8 moieties yet having an anti-Xa Yin-Wessler activity and including a sequence consisting of less than 8 moieties, which sequence is responsible, to a large extent, for the specific anti-Xa activity of the products;
- oligosaccharides can be characterized by the fact they possess a specific structure capable of binding ATIII. They have an anti-Xa activity higher than heparin and a very low global anticoagulant activity.
- the products having an ATIII affinity as recovered from the above mentioned process are submitted to one or several steps in order to selectively separate the above-defined oligosaccharides having short chains.
- FIG. 1 is an elution diagram of a depolymerization heparin mixture according to Example 2 of the present invention fractionated by gel filtration on a DEAE Sephadex A 25 column.
- FIG. 2 is an elution diagram of fractions obtained by filtration of the unfixed and fixed products of Example 3 of the present invention on columns of Sephadex G-50 Superfine gel.
- FIG. 3 is an elution diagram of degraded FPA oligosaccharide chains fragmented into di and tetrasaccharides according to the present invention wherein the di- and tetrasaccharides are separated by chromatography on a column of Sephadex G-50.
- FIG. 4 is a graphical representation of anti-factor Xa active hexasaccharide fraction obtained by chromatography of depolymerized heparin products on a column of Sephadex G-50 Superfine gel.
- FIG. 5 is the 13 C NMR characterization of an octasaccharide fraction according to Example 3 of the present invention.
- FIG. 6 is the 13 C NMR characterization of an octasaccharide fraction according to Example 1 of the present invention..Iaddend.
- Said separation is advantageously obtained by fractionating the mixture of the eluted products having ATIII affinity, according to their molecular weight and/or their ionic density, and recovering the desired fractions.
- the fractionation can be carried out directly on the depolymerization mixture.
- the fractions comprising short oligosaccharidic chains advantageously the oligosaccharides per se, can be isolated.
- the fractions, optionally the oligosaccharides, with a high ATIII affinity are subsequently separated by resorting to a step comprising contacting said fractions as above mentioned with ATIII.
- oligosaccharidic fractions of the invention are of the type of those obtained by resorting to the various steps defined above. They are characterized by the fact that they are free of oligosaccharides comprising more than 8 saccharidic moieties and that they consist of oligosaccharides having no more than 8 saccharidic moieties containing a sequence comprising less than 8 saccharidic moieties, responsible for their anti-Xa activity at least to a major extent.
- the fractions of the invention are of the type obtainable by a process wherein the heparinic material is depolymerized by a chemical process, in particular with nitrous acid, HNO 2 , in aqueous medium.
- the heparinic chains are thus split between a N-sulfate glucosamine unit and the following uronic acid resulting in chains containing a 2,5-anhydromannose group at their reducing end.
- the depolymerization is carried out under an enzymatic process, advantageously with a highly purified heparinase, more especially a bacterial heparinase.
- the enzyme cleaves the heparinic chains between the anomeric carbon of an N-sulfate-glucosamine residue and the following uronic acid unit.
- the depolymerization with the purified heparinase is advantageously carried out under conditions giving rise to said biologically active oligosaccharides having no more than 8 saccharide moieties and for part of them of 6 or less. Said conditions are such that the limit of the enzymatic reaction is reached. In other words the resulting oligosaccharides are then no longer susceptible to the action of the highly purified heparinase.
- the biologically active oligosaccharides correspond to those separable from said depolymerization mixtures (obtained by chemical or enzymatic way) by adsorption on carrier bound ATIII such as agarose bound ATIII under conditions enabling the products having an ATIII affinity to be fixed or retained on ATIII while those devoid of such an affinity are eliminated for example by rinsing.
- carrier bound ATIII such as agarose bound ATIII
- the depolymerization mixture is submitted to a fractionation as already mentioned, to separate the desired chains.
- a separation is advantageously carried out by gel permeation (gel filtration).
- oligosaccharidic chains such as those above isolated, besides their high AT III affinity and subsequent anti-Xa activity are characterized by NMR spectra comprising among others a characteristic signal in the region of the C-2 of N-sulfate-glucosamine residues (said signal is marked by an asterisk on FIGS. 5 and 6). This signal does not appear with heparin. Very likely it can be related to the presence of a 3-O substituent and more particularly to a 3-O-sulfate group on a N-sulfate-D-glucosamine moiety.
- the oligosaccharides are further characterized by a Yin-Wessler titer and a USP titer which are respectively in a ratio of at least 30, preferably of at least 100.
- Preferred oligosaccharidic fractions and oligosaccharides comprise those with an AT III affinity and an anti-Xa (Yin-Wessler) activity which are higher than heparin.
- Such an anti-Xa activity can be 10 times as high as the one of heparin.
- Activity higher than 100 iu/mg can be noticed for certain oligosaccharides. Values above 700 ui/mg or of at least 1,000 iu/mg, even 1,200, reaching 2,000 iu/mg or more have been observed for other oligosaccharides.
- Active oligosaccharides of the invention have a N-sulfated D-glucosamine residue advantageously 3-O sulfated (designated F in the formula given hereafter).
- oligosaccharides further comprise a N-acetyl-D-glucosamine residue (D) and/or a D-glucuronic acid residue (E) and/or a 2-O sulfate-L-iduronic acid residue (G) and/or a N-sulfate-D-glucosamine residue (H).
- oligosaccharides In other oligosaccharides, the presence of the following saccharidic moieties is observed i.e. a 2-O sulfate,4,5-unsaturated uronic acid (A) and/or a N-sulfate D-glucosamine unit (B) and/or a L-iduronic acid unit (C).
- A 2-O sulfate,4,5-unsaturated uronic acid
- B N-sulfate D-glucosamine unit
- C L-iduronic acid unit
- Preferred oligosaccharides of the invention have a N-sulfate-D-glucosamine residue at their reducing end. This residue is sulfated or not in positions 3 and/or 6.
- oligosaccharides contain all the residues hereabove indicated.
- oligosaccharides of the invention appear thus to be characterized by the presence of one N-acetyl-D-glucosamine moiety for two N-sulfate-glucosamine moieties.
- oligosaccharides are characterized by the presence of one N-acetyl-D-glucosamine moiety for three N-sulfate-D-glucosamine moieties.
- An oligosaccharide of that type is constituted by an octasaccharide corresponding to the following ABCDEFGH sequence: ##STR1##
- R represents an hydrogen atom or a sulfate (SO 3 - ) group.
- Another octasaccharide has ABGHCDEF sequence.
- Active hexasaccharides of the invention also include moieties among said A,B,C,D,E,F,G and H moieties.
- One of these species has ABCDEF sequence.
- Another species has CDEFGH sequence wherein C is an unsaturated uronic acid.
- CDEFGH sequence Another species is constituted by CDEFGH sequence (but where C is an iduronic acid residue).
- active oligosaccharides are pentasaccharides, more particularly the one having DEFGH structure.
- Shorter oligosaccharidic chains still biologically active are part of the present invention.
- the pharmaceutically acceptable salts of said oligosaccharides are part of the invention as well.
- the invention also aims at providing a process for obtaining fractions such as above disclosed, comprising heparin depolymerization and the treatment of the resulting depolymerization mixture so as to separate the fractions containing oligosaccharides having no more than 8 saccharidic moieties (advantageously the oligosaccharides per se) having a high AT III affinity and a high anti-Xa (Yin-Wessler) activity.
- the depolymerization step is carried out under mild conditions so that the oligosaccharidic chains are not completely degradated and the moieties which are responsible (to a large extent) for anti-Xa (Yin-Wessler) activity are maintained.
- the depolymerizing conditions of the process defined hereabove are so adjusted as to maintain the capability of at least a part of the resulting oligosaccharides of being specifically retained on immobilized antithrombin III.
- the above adjustment can also advantageously be based on the upkeeping of the capability of at least part of the resulting oligosaccharides to exhibit anti-Xa activity as measurable by the Yin-Wessler test, while having practically no more anticoagulant activity as measured by the USP test.
- the threshold with respect to the adjustment of the depolymerization conditions need not necessarily be attained. It is nevertheless desirable to do so when high yields of oligosaccharides having Yin-Wessler anti-Xa activity are desired.
- heparinase When depolymerization with heparinase, a highly purified heparinase should preferably be used, in particular a bacterial heparinase, more especially originating from Flavobacterium heparinum.
- the conditions are controlled in order to obtain the smallest fragments still having an affinity for AT III and an anti-Xa (Yin-Wessler) activity.
- the depolymerization with the heparinase may optionally be carried out on the fractions resulting from the oligosaccharidic fractions obtained after degradation of heparin with HNO 2 , or also on the oligosaccharides of higher molecular weight which are retained on immobilized AT III togetherwith the active oligosaccharides having less than 8 moieties and which are then eluted with these oligosaccharides having shorter chains.
- the separation and the recovery of the fractions which contain the desired oligosaccharides is advantageously carried out by affinity chromatography in a column containing bound AT III.
- the column is advantageously equilibrated with a buffer having an ionic strength of about 0.2 M, preferably not less than 400.1 M, at a pH of 6 to 8, preferably close to or slightly higher than neutral.
- a preferred embodiment for recovering the AT III retained or absorbed products, having an anti-Xa activity comprises desorbing and recovering all of the oligosaccharides by eluting them with a buffer having a sufficient ionic strength to that effect.
- the buffer used for the above mentioned elution is further advantageously selected among those which do not interfere with the subsequent recovery steps (particularly with alcohol precipitation) of the oligosaccharides contained in the recovered fractions.
- a sodium salt can also be used.
- an alcoholic precipitation is advantageously carried out to recover them, their separation being then made for example by centrifugation.
- the last mentioned fractionation is so monitored that after the larger molecules have been eluted, the smaller ones are recovered, starting from those fractions which have a Yin-Wessler titer and a USP titer which are in a ratio of at least 30, preferably 100, the recovery extending to all the remaining fractions which still exhibit anti-Xa activity at least in the Yin-Wessler test.
- the volume of the successively eluted fractions will be selected as a matter of routine in order to select the most appropriate fractions with respect to the desired application.
- the oligosaccharides having more than 8 saccharidic moieties are eliminated from the depolymerization mixture, advantageously by gel filtration or a similar process as indicated above.
- Biologically active octa-, hepta-, hexa-, penta-, tetra- and trisaccharides can be isolated from the eluted fractions obtained.
- the pharmacological study of the fractions and oligosaccharides of the invention has shown a relationship between their anti-Xa activity as expressed in Yin-Wessler units and their antithrombotic activity.
- thrombus has been caused in the jugular vein of the rabbit by injecting a complex of activated prothrombin.
- Said octasaccharide appears then to have a strong antithrombotic activity.
- global anticoagulant activity is not detectable.
- the oligosaccharide fractions according to the invention are free of toxicity.
- the administration of 10,000 U/kg (Yin-Wessler titer) of any of the fractions according to the invention causes in the rabbit neither any toxic reaction nor any pyrogenic effect in the pyrogenicity test in the rabbit according to the French Pharmacopea.
- compositions according to the invention are then particularly suitable for controlling specifically some steps of the coagulation in man or animal, more particularly when selective control of the activity of the blood factor Xa is desired (by way of example only, in patients, who are to undergo or who underwent surgery, in atheromatous diseases, perturbations of the coagulation mechanisms by bacterial or enzymatic activators, etc . . . )
- the invention relates then to pharmaceutical preparations which contain oligosaccharidic fractions or the oligosaccharides themselves with high anti-Xa activity.
- It relates more particularly to pharmaceutical preparation devoid of pyrogenic substances, containing an effective amount of active principles, in association with pharmaceutical excipients.
- compositions in which the pharmaceutical vehicle is suitable for the administration by oral route are suitable for the administration by oral route.
- dosage forms of the invention suitable for the administration by oral route can advantageously be gastroresistant capsules, or tablets or pills.
- compositions include oligosaccharides or oligosaccharidic fractions in association with excipients suitable for the administration by rectal route.
- Corresponding dosage forms are suppositories.
- dosage forms of the invention are sprays or ointments.
- the invention also concerns pharmaceutical compositions which are injectable, sterile or sterilizable.
- Such solutions advantageously contain 1,000 to 100,000 U (Yin-Wessler)ml of the oligosaccharidic fraction, preferably from 5,000 to 50,000 for example 25,000 U/ml, when these solutions are intended for subcutaneous injection or containing again, for example, from 500 to 10,000 for example, 5,000 units/ml of the oligosaccharidic fraction or oligosaccharide when they are intended for intravenous injection or for perfusion.
- U Yin-Wessler
- these pharmaceutical preparations are presented in the form of non-reusable syringes, ready for use at any suitable time.
- the invention also concerns pharmaceutical compositions containing said oligosaccharides in association with another active principle, in particular useful for the prophylaxis and the treatment of thrombosis such as a veinotonic agent like dihydroergotamine, a salt of nicotinic acid or a thrombolytic agent like urokinase.
- a veinotonic agent like dihydroergotamine
- a salt of nicotinic acid or a thrombolytic agent like urokinase.
- oligosaccharidic fractions and oligosaccharides of the invention are advantageously in the form of a salt of at least one physiologically acceptable metal, such as sodium and/or calcium and/or magnesium.
- compositions according to the invention are particularly adapted to the control (preventive or curative) of the blood coagulation in man or animal, notably in those cases where the host is subjected to risks of hypercoagulability, more particularly those resulting from the release by the organism of thromboplastin, for example, of tissular thromboplastin (surgical operations, atheromatous processes, tumor development, disturbances of the coagulation mechanisms by bacterial or enzymatic activators, etc . . . ).
- a posology capable of being used in man comprises for example, the administration to the patient of 1,000 to 25,000 U by the sub-cutaneous route, 2 to 3 times daily, according to the level of hypercoagulation risk or the thrombotic condition of the patient, or from 1,000 to 25,000 U per 24 hours by the intravenous route, in discontinuous administration at regular intervals or continuously by perfusion, or again from 1,000 to 25,000 U (three times weekly) by the intramuscular route (titers expressed in Yin-Wessler U).
- the doses should naturally, be adjusted in each patient according to the results of previously effected blood analyses, the nature of the disorder from which the patient is suffering and, generally, his state of health, as is well known.
- the invention also relates to the application of the oligosaccharides according to the invention for the preparation of a biological reactant usable in the laboratory, notably as a comparison reference for the study of other substances of which the anticoagulant activity is to be tested, notably at the level of inhibition of the factor Xa.
- Method for obtaining oligosaccharidic fractions including the steps of:
- heparin (USP titer: 150 UI/mg, YIN-WESSLER titer: 150 U/mg) were dissolved in 800 ml of water at room temperature. 200 ml of 0.5 M sulfuric acid and then 13.8 g of sodium nitrite were then added (final molarities of sulfuric acid: 0.1 M, and of the nitrite: 0.2 M). A reaction accompanied by the release of gaseous nitrogen was then produced. The reaction was stopped 15 minutes later by adjusting the pH at 7-7.2 with 5 N sodium hydroxide. The depolymerization products were precipitated by ethanol (7 volumes) that is, in this case, 7 liters. The precipitate was centrifuged, washed with alcohol and dried under vacuum.
- the apparent increase of weight of the precipitate was due to partial precipitation of sodium sulfate together with the depolymerization products.
- the retained oligosaccharides were then eluted from the column by a buffer capable of desorbing all of the oligosaccharides retained on the immobilized antithrombin III (CaCl 2 0.2 M, tris-HCl 0.05 M, pH 7.2). The part of effluent which contained the oligosaccharides was recovered and the said oligosaccharides were precipitated by 10 volumes of ethanol.
- the products so obtained consisted of a mixture of mucopolysaccharides of high molecular weight and of oligosaccharides of low molecular weight.
- the contents of the tubes were pooled to form the fractions numbered 1 to 5.
- the mucopolysaccharides contained in each of these fractions were precipitated by alcohol and dried.
- Fraction 4" was found to consist of an oligosaccharide having less than 8 saccharide units and most likely not more than 6 saccharide units, and "fraction 5" of an oligosaccharide having less than 6 saccharides, most likely not more than 4 saccharide units.
- Method for obtaining oligosaccharidic fractions including the steps of:
- Flavobacterium heparinum enzymes were used for degradating heparin.
- the enzymes of flavobacterium heparinum were cultivated according to the method of Payza and Korn in J. Biol. Chem. 1956, 223, p. 853-858.
- the lyophilized cells were crushed under dry conditions in the presence of alumine and extracted by an acetate buffer at neutral pH.
- heparin for use in therapy was dissolved in 50 ml of distilled water. 1 g of sodium acetate and 100 mg of calcium chloride were added thereto. The pH was adjusted to 7.2 by ClHO. 1 N.
- a column having a 16 mm diameter containing 50 ml of the gel known under the above commercial designation was equilibrated with a 0.1 M NaCl, pH 7.0 buffer.
- 20 ml of a solution of 180 mg of the above product P in said buffer were deposited on the top of the column and eluted with a gradient formed starting from 250 ml of a 0.1 M NaCl, pH 7.0 buffer, on the one hand, and of a 0.5 M CaCl 2 pH 7.0 buffer, on the other hand.
- the flow rate was adjusted to 30 ml per hour. Successive 10 ml volumes were recovered.
- the elution diagram (followed by optical density measurements at 232 nm) is represented on FIG. 1.
- the volumes were pooled into fractions 1, 2, 3, 4 according to the optical density measurements, as shown in FIG. 1. Their respective optical densities are shown in table 1 hereafter.
- a column having a diameter of 2.5 cm containing 50 ml of agarose having AT III immobilized thereon was equilibrated with 0.1 M. NaCl tris-HCl 0.025 M; pH 7.4.
- the first eluant used was the same as above: an effluent containing 50 mg of a product referred to as P 2 (B) contained in the first detected peak of optical density at 232 nm was separated therewith.
- composition results as to composition are summed up in table II hereafter, expressed as weight % (first line), as the mole to mole ratio with respect to the glucosamine units after hydrolysis (H + ) according to the technique of Smith and Gilkerson (second line).
- oligosaccharides of the invention comprise substantially:
- the molecular weight of the fraction according to the invention was approximated by its time of elution (of of retention on the columns) with reference to the linear variations of the retention times of standard polystyrene-sulfonates of known molecular weights (of respectively 4,000, 6,500, 16,000 and 31,000) as well as of a tetrasaccharide having a known molecular weight of 700-900 subjected to the same assays, as a function of the logarithm values corresponding to said molecular weights.
- the measurements were made using a SPECTRAPHYSICS 3500 chromatograph, and the detection of the fraction by UV spectrophotometry (200 m ⁇ and 230 m ⁇ ).
- UV-absorption was carried out on a solution of 100 ⁇ /ml of P 2 (A) and in an UV band of 215-260 nm. Maximum absorption was observed in the 230-235 nm band.
- Method for obtaining oligosaccharidic fractions including the steps of:
- heparin for use in therapy 20 mg were dissolved in 100 ml of an acetate buffer (NaOAc 0.15 M, NaCl 0.15 M; Ca Cl 2 0.005 M; pH 6.9).
- the solution was incubated for 24 hours at 30° C.
- a chromatography column (5 ⁇ 18 cm) containing 10 mg of bound AT III/ml of Sepharose was equilibrated with 0.1. M Na Cl; tris-HCl 0.05 M; pH 7.5. 2 g of the products of degradation of heparin were deposited on the top of the column.
- the column was rinsed with said buffer whereby the unfixed fractions were eliminated (the corresponding products being designated as UP hereinafter).
- the fixed products (designated as F P-were then eluted with a solution of CaCl 2 1 M pH 7.2.
- the products were precipitated with alcohol and recovered by centrifugation.
- 1.6 g UP on the one hand and 8 mg of FP having 800 ui/mg (Yin-Wessler), on the other hand are thus recovered.
- FIG. . .3.!. .Iadd.2 .Iaddend. represents the elution diagrams of UP fractions (continuous line) and FP (fractions (dotted line).
- the elution has been controlled by optical density measurements at 230 nm (absorption wavelength of the double bond created by the heparinase).
- UP fraction was fractionated into di-, tetra-, hexa- and octasaccharides (UP 2 , UP 4 , UP 6 and UP 8 ) and into another product having a higher polymerization degree (UP +8 ).
- UP 8 and UP +8 do not appear on the elution curve of FIG. 2 as they only represent a very low percentage (3.4 and 1.3% respectively) and are only detected at high sensitivity.
- FP fraction was separated into four fractions designated FPa,b,c and d, according to the order of the decreasing elution volume. The major part of FP fractions is eluted slightly before UP fraction.
- each of said fractions comprises: the elution volume (ml) of each of said fractions, issued from UP and FP fractions; the % of each of them in the mixture of the UP and FP fractions respectively, the specific rotatory power of each fraction (measured with an electronic polarimeter in aqueous solutions usually 1%); the absorbance at 230 mn (measured in a 0.01% solution in HCl 0.03 M, the results being expressed as optical density of 1% solution); and the anti-Xa activity in human plasma of FP fractions measured according to the test of Yin and Wessler above mentioned.
- the FPa fractions recovered after the gel filtration were incubated with HNO 2 in an aqueous medium under conditions enabling degradation of the oligosaccharidic chains.
- the degradation was carried out according to the method of Shiveley and Conrad in Biochemistry 1976, 15, p. 3932-3942.
- optical density measurement of these fractions shows that the major part of the unsaturated molecules are disaccharides, 90% or the optical density being in the peak of the disaccharide while 10% are in the peak of the tetrasaccharidic fragment.
- the tetrasaccharidic unit does not contain an uronic acid moiety with a double bond.
- Such moiety is part of a disaccharide which contains further an N-sulfoglucosamine, this disaccharide GH is located at the non reducing end of the oligosaccharide before its nitrous degradation.
- the reducing ends of the chains are not converted into 2,5-anhydro-mannose during the nitrous degradation.
- the reduction is carried out with a sodium borohydride buffer at pH 9.5.
- the reducing ends of the FPa oligosaccharidic chains are then converted into tritiated hexitols.
- the reduced product is separated from the salts present in the mixture by filtration on Sephadex G 25. It is then submitted to nitrous acid degradation and gel filtration as described above.
- the dosage of 2,5-anhydro-mannose groups is then carried out and shows a clear decrease of said groups in the disaccharidic fraction while the tetrasaccharidic fractions remain practically unchanged.
- the FPa fraction was further submitted to a nitrous acid degradation under very mild conditions. It was thus possible to obtain, after gel filtration and affinity chromatography an oligosaccharide fraction containing mainly the two hexasaccharides with ABCDEF and CDEFGH sequences the latest being also part of the invention.
- CDEFGH and ABCDEF Two main species, i.e. CDEFGH and ABCDEF were found in the eluted fractions, as shown by the analytical methods described above for study of the FPa fraction. They still had a high anti-Xa activity (Yin and Wessler).
- the octasaccharidic fraction was isolated. It presented a YW titer of 2000 IU/mg and an APTT titer of 4 IU/mg. The 13 C NMR spectrum of this product was recorded (see FIG. 5). If confirms that the product is an octasaccharide. It also confirms the assigned structure (ABCDEFGH sequence). The signals observed are respectively characteristic of the:
- the elution was performed with 0.2 M sodium chloride.
- the products were detected by U.V absorption at 232 nm (see FIG. 4).
- the major part of the product was eluted in the octasaccharidic region, and presented the same properties as the product previously described.
- This compound was highly active in the YW test: 510 IU/mg. Its APTT titer was 3IU/mg. Since this hexasaccharidic fraction is obtained after heparinase degradation, it contains the residues A and H characterized in the octasaccharidic fraction. Moreover, since this product presents affinity for ATIII it should contain a CDEF tetrasaccharidic sequence. Thus it can be represented by ABCDEF structure.
- 2--Said octasaccharide is submitted to the action of a purified heparitinase, extracted from Flavobacterium heparinum.
- the experimental conditions correspond to those used in the enzymatic degradation according to example 2.
- Two tetrasaccharides to which structures EFGH and ABCD can be given are recovered by filtration on SEPHADEX G 50 (carried out as in example 2). By passing the tetrasaccharides through a column of Sepharose ATIII, EFGH is be retained while ABCD is eliminated. EFGH is then recovered by elution with a solution NaCl 1 M.
- the Yin-Wessler activity measured in various assays, is about 100-200 ui/mg.
- 3--Octasaccharide ABCDEFGH is submitted to a mild nitrous degradation.
- 1 mg of octasaccharide is used per ml of solution--HNO 2 is generated in situ by adding NaNO 2 N/1000 and Hcl.
- the pH is adjusted to 3.
- the reaction mixture is submitted to a gel filtration followed by an affinity chromatography, using the conditions disclosed in the preceeding examples.
- NaCl 1 M or CaCl 2 1 M By elating with NaCl 1 M or CaCl 2 1 M, a product can be recovered having presumably hexasaccharidic structure CDEFGH.
- Said product is submitted to the action of an iduronidase extracted from human kidney.
- the enzymatic degradation step is carried out at pH 7 at 37° C.
- This glucosamine unit is sulfated or not in position 6.
- the integral curve confirms that the product has an average number of moieties of less than 8 and comprises a major part of hexasaccharidic and octasaccharidic species.
- the invention extends of course to the oligosaccharides that may be obtained by other depolymerization techniques of heparin or heparinic compounds followed by the subsequent recovery of the oligosaccharides of low molecular weight having anticoagulant activity as measurable by the YIN-WESSLER test.
Abstract
Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a USP titer in a ratio of at least 30. They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.
Description
This application is a continuation-in-part of patent application Ser. No. 091,164, filed Nov. 5, 1979, which application has been abandoned in favor of pending application Ser. No. 204,505 filed Nov. 6, 1980.
The invention relates to oligosaccharidic fractions and to oligosaccharides having biological properties, particularly the ability of more specifically controlling some steps of the blood coagulation.
The invention also relates to processes for obtaining said products and to the use of said products as active principles in drugs.
The invention relates more particularly to oligosaccharides having a highly selective activity against activated factor X or factor Xa of blood i.e. a strong antithrombotic activity, while avoiding the risk of hemorrhage for the patient, as well as to oligosaccharidic fractions containing such oligosaccharides (the term "oligosaccharidic fractions" is used in the specification and the claims to designate a relatively homogeneous mixture of oligosaccharidic fragments or chains having a variable number of saccharidic moieties).
The inventors have been led to investigate the biologically active oligosaccharidic fractions and the oligosaccharides themselves, such as obtained from heparin.
It will be noted that the term heparin is used in the specification and the claims in its broadest sense, in order to designate either a commercial heparin of pharmaceutical grade or a crude heparin such as obtained by extraction from biological material, particularly from mammalian tissue.
It is admitted that heparin is an heterogeneous polysaccharide with respect to the composition of its oligosaccharidic chains as well as to the molecular weight thereof.
It is generally considered that heparin mainly contains 2-O-sulfate-L-iduronic acid and N-sulfate-D glucosamine (6-O-sulfated or not) and to a lesser extent D-glucuronic acid, L-iduronic acid and N-acetyl-D-glucosamine (6-O-sulfated or not) moieties.
It is also known that heparin produces its anticoagulant activity by potentiating the inhibitory effect of antithrombin III (αATIII) which is a plasma protein against the successive enzymatic reactions of the coagulation cascades. As heparin is able to simultaneously depress a large number of the coagulation factors participating in the creation and the unkeeping of different forms of hypercoagulability, its activity does not appear specific but general.
Although this anticoagulant activity turns out to be valuable, the re-equilibration of the coagulation-fibrinolysis system with patients under treatment is delicate, due to the global nature of its action. As a result the administration (in order to prevent hypercoagulation risks, for example, the spectre of post-surgical thrombosis) of too high doses of anticoagulant drug or the insufficient selectivity of that drug can be responsible for serious hemorrhages.
By thoroughly studying various conditions for depolymerizing heparin and the depolymerization mixtures thus obtained, the inventors have been led to notice that under certain conditions, it is possible to obtain valuable antithrombotic oligosaccharides containing mixtures. These oligosaccharides are more satisfactory than heparin with regard to the specificity of their activity. They are more particularly capable of enhancing the specific activity of ATIII with respect to a smaller number of coagulation factors, more especially with respect to factor Xa. More essentially, it has been found that such fractions and oligosaccharides have a low global anticoagulant activity as measured by the USP method and that consequently the ratio of their anti-Xa activity as expressed in Yin-Wessler units and of their USP titer is high, at least 30.
As is well-known, the Yin-Wessler activity is more specifically representative of the capability of the active fractions to potentiate the inhibition of the activated factors Xa of blood by AT III in the corresponding test and the UPS titer is representative of the capability of the active fractions to inhibit the global coagulation of blood or plasma.
The Yin-Wessler titer is measured by the test described by these authors in J. Lab. Clin. Med. 1976,81,298-300, and the U.S.P. titer is measured by the test which is described in the "Pharmacopea of the United States of America", XIX, pp. 229-230 (see also the second supplement U.S.P.--NF, p, 62 and the fourth supplement U.S.P.--NF p. 90 respectively entitled "Drug Substances" and "Dosage Forms".
Unexpectedly, it has thus been noticed that the desired anti-Xa specific activity was found in the short oligosaccharidic chains, i.e. containing no more than 8 saccharidic moieties, which can be isolated from the depolymerization mixtures by resorting to certain purification steps, carried out under specified conditions.
It will be noted that the terms "saccharidic moiety" is used in the specification and the claims to designate monosaccharides contained in the heparinic chains.
Besides, according to an aspect of great interest, the inventors have found that the anti-Xa activity of said fractions and of the oligosaccharides, such as expressed in Yin-Wessler units, was significant of an antithrombotic activity in vivo.
It is then an object of the invention to provide new oligosaccharides and fractions containing them, having a high anti-Xa activity and a remarkable selectivity in the framework of the successive enzymatic reactions which characterize the coagulation processes. It is another object to provide structural features of these oligosaccharides.
It is a further object of the invention to provide a process of obtaining said fractions which is easy to carry out.
It is still another object of the invention to provide active principles of drugs and the drugs per se, particularly capable of inhibiting the factor Xa with a high degree of selectivity while their activity on global coagulation can be maintained at a very low level. Such drugs are advantageously useful for antithrombotic treatment without haemorrhage risks.
Said oligosaccharidic fractions are of the type obtainable by a process which comprises the steps of
contacting heparin (or heparinic fractions) possessing anticoagulant activity and having chains with molecular weights ranging from about 2000 to about 50000, with an agent capable of depolymerizing or fragmenting the heparinic chains, the conditions used for carrying out that step being adjusted so as to obtain a depolymerization mixture which contains oligosaccharidic fragments or chains, constituted by no more than 8 moieties yet having an anti-Xa Yin-Wessler activity and including a sequence consisting of less than 8 moieties, which sequence is responsible, to a large extent, for the specific anti-Xa activity of the products;
treating the depolymerization mixture to separate at least the major part of the above defined oligosaccharidic chains, said treatment advantageously comprising (a) the contact of the depolymerization mixture with ATIII for selecting at least the major part, advantageously practically the totality of the oligosaccharides possessing a sequence having the specific structure necessary to recognize and bind ATIII, (b) the elimination of the unselected products, (c) the recovery of the selected products. Said oligosaccharides can be characterized by the fact they possess a specific structure capable of binding ATIII. They have an anti-Xa activity higher than heparin and a very low global anticoagulant activity.
The products having an ATIII affinity as recovered from the above mentioned process, are submitted to one or several steps in order to selectively separate the above-defined oligosaccharides having short chains.
FIG. 1 is an elution diagram of a depolymerization heparin mixture according to Example 2 of the present invention fractionated by gel filtration on a DEAE Sephadex A 25 column.
FIG. 2 is an elution diagram of fractions obtained by filtration of the unfixed and fixed products of Example 3 of the present invention on columns of Sephadex G-50 Superfine gel.
FIG. 3 is an elution diagram of degraded FPA oligosaccharide chains fragmented into di and tetrasaccharides according to the present invention wherein the di- and tetrasaccharides are separated by chromatography on a column of Sephadex G-50.
FIG. 4 is a graphical representation of anti-factor Xa active hexasaccharide fraction obtained by chromatography of depolymerized heparin products on a column of Sephadex G-50 Superfine gel.
FIG. 5 is the 13 C NMR characterization of an octasaccharide fraction according to Example 3 of the present invention.
FIG. 6 is the 13 C NMR characterization of an octasaccharide fraction according to Example 1 of the present invention..Iaddend.
Said separation is advantageously obtained by fractionating the mixture of the eluted products having ATIII affinity, according to their molecular weight and/or their ionic density, and recovering the desired fractions.
Alternatively, the fractionation can be carried out directly on the depolymerization mixture. At that stage, the fractions comprising short oligosaccharidic chains, advantageously the oligosaccharides per se, can be isolated. The fractions, optionally the oligosaccharides, with a high ATIII affinity are subsequently separated by resorting to a step comprising contacting said fractions as above mentioned with ATIII.
The oligosaccharidic fractions of the invention are of the type of those obtained by resorting to the various steps defined above. They are characterized by the fact that they are free of oligosaccharides comprising more than 8 saccharidic moieties and that they consist of oligosaccharides having no more than 8 saccharidic moieties containing a sequence comprising less than 8 saccharidic moieties, responsible for their anti-Xa activity at least to a major extent.
According to an embodiment, the fractions of the invention are of the type obtainable by a process wherein the heparinic material is depolymerized by a chemical process, in particular with nitrous acid, HNO2, in aqueous medium.
The heparinic chains are thus split between a N-sulfate glucosamine unit and the following uronic acid resulting in chains containing a 2,5-anhydromannose group at their reducing end.
In another embodiment, the depolymerization is carried out under an enzymatic process, advantageously with a highly purified heparinase, more especially a bacterial heparinase.
The enzyme cleaves the heparinic chains between the anomeric carbon of an N-sulfate-glucosamine residue and the following uronic acid unit.
Its action produces a mixture of oligosaccharides (di-,tetra-,hexa-,octasaccharides) with a two fold degree of polymerization and terminated at their non reducing end by an α,β-unsaturated uronic acid.
The depolymerization with the purified heparinase is advantageously carried out under conditions giving rise to said biologically active oligosaccharides having no more than 8 saccharide moieties and for part of them of 6 or less. Said conditions are such that the limit of the enzymatic reaction is reached. In other words the resulting oligosaccharides are then no longer susceptible to the action of the highly purified heparinase.
The biologically active oligosaccharides then correspond to those separable from said depolymerization mixtures (obtained by chemical or enzymatic way) by adsorption on carrier bound ATIII such as agarose bound ATIII under conditions enabling the products having an ATIII affinity to be fixed or retained on ATIII while those devoid of such an affinity are eliminated for example by rinsing.
This is followed by the elution of the retained or adsorbed products in order to recover them, and by their fractionation for isolating the short chains having an anti-Xa activity.
Optionally, before said separation based on the AT III affinity of the fractions, the depolymerization mixture is submitted to a fractionation as already mentioned, to separate the desired chains. Such a separation is advantageously carried out by gel permeation (gel filtration).
Most of the oligosaccharidic chains such as those above isolated, besides their high AT III affinity and subsequent anti-Xa activity are characterized by NMR spectra comprising among others a characteristic signal in the region of the C-2 of N-sulfate-glucosamine residues (said signal is marked by an asterisk on FIGS. 5 and 6). This signal does not appear with heparin. Very likely it can be related to the presence of a 3-O substituent and more particularly to a 3-O-sulfate group on a N-sulfate-D-glucosamine moiety.
The oligosaccharides are further characterized by a Yin-Wessler titer and a USP titer which are respectively in a ratio of at least 30, preferably of at least 100.
Preferred oligosaccharidic fractions and oligosaccharides comprise those with an AT III affinity and an anti-Xa (Yin-Wessler) activity which are higher than heparin. Such an anti-Xa activity can be 10 times as high as the one of heparin. Activity higher than 100 iu/mg can be noticed for certain oligosaccharides. Values above 700 ui/mg or of at least 1,000 iu/mg, even 1,200, reaching 2,000 iu/mg or more have been observed for other oligosaccharides.
Active oligosaccharides of the invention have a N-sulfated D-glucosamine residue advantageously 3-O sulfated (designated F in the formula given hereafter).
Other oligosaccharides further comprise a N-acetyl-D-glucosamine residue (D) and/or a D-glucuronic acid residue (E) and/or a 2-O sulfate-L-iduronic acid residue (G) and/or a N-sulfate-D-glucosamine residue (H).
In other oligosaccharides, the presence of the following saccharidic moieties is observed i.e. a 2-O sulfate,4,5-unsaturated uronic acid (A) and/or a N-sulfate D-glucosamine unit (B) and/or a L-iduronic acid unit (C).
Preferred oligosaccharides of the invention have a N-sulfate-D-glucosamine residue at their reducing end. This residue is sulfated or not in positions 3 and/or 6.
Some of the oligosaccharides contain all the residues hereabove indicated.
The dosage by colorimetry of N-acetyl-glucosamine units, according to the method of Smith and Gilkerson in Annal. Biochem. 1979,98, p. 478-480, shows then the presence of about one molecule of N-acetylglucosamine by oligosaccharidic chain. Glucosamine dosage before and after acid hydrolysis allows for determination of the repective amount of N-sulfate and N-acetyl-glucosamine.
Some oligosaccharides of the invention appear thus to be characterized by the presence of one N-acetyl-D-glucosamine moiety for two N-sulfate-glucosamine moieties.
Other oligosaccharides are characterized by the presence of one N-acetyl-D-glucosamine moiety for three N-sulfate-D-glucosamine moieties.
An oligosaccharide of that type is constituted by an octasaccharide corresponding to the following ABCDEFGH sequence: ##STR1##
In the above formula R represents an hydrogen atom or a sulfate (SO3 -) group.
Another octasaccharide has ABGHCDEF sequence.
Active hexasaccharides of the invention also include moieties among said A,B,C,D,E,F,G and H moieties. One of these species has ABCDEF sequence.
Another species has CDEFGH sequence wherein C is an unsaturated uronic acid.
Another species is constituted by CDEFGH sequence (but where C is an iduronic acid residue).
Other active oligosaccharides are pentasaccharides, more particularly the one having DEFGH structure.
Shorter oligosaccharidic chains still biologically active are part of the present invention.
The pharmaceutically acceptable salts of said oligosaccharides are part of the invention as well.
The invention also aims at providing a process for obtaining fractions such as above disclosed, comprising heparin depolymerization and the treatment of the resulting depolymerization mixture so as to separate the fractions containing oligosaccharides having no more than 8 saccharidic moieties (advantageously the oligosaccharides per se) having a high AT III affinity and a high anti-Xa (Yin-Wessler) activity.
The depolymerization step is carried out under mild conditions so that the oligosaccharidic chains are not completely degradated and the moieties which are responsible (to a large extent) for anti-Xa (Yin-Wessler) activity are maintained.
Preferably, the depolymerizing conditions of the process defined hereabove are so adjusted as to maintain the capability of at least a part of the resulting oligosaccharides of being specifically retained on immobilized antithrombin III.
The above adjustment can also advantageously be based on the upkeeping of the capability of at least part of the resulting oligosaccharides to exhibit anti-Xa activity as measurable by the Yin-Wessler test, while having practically no more anticoagulant activity as measured by the USP test.
It will be appreciated that the threshold with respect to the adjustment of the depolymerization conditions need not necessarily be attained. It is nevertheless desirable to do so when high yields of oligosaccharides having Yin-Wessler anti-Xa activity are desired.
When depolymerizing heparin with HNO2, it seems advantageous to carry out the reaction in aqueous medium, at a pH ranging from 2 to 4, preferably 3 and at a temperature close to ambient.
When depolymerization with heparinase, a highly purified heparinase should preferably be used, in particular a bacterial heparinase, more especially originating from Flavobacterium heparinum. The conditions are controlled in order to obtain the smallest fragments still having an affinity for AT III and an anti-Xa (Yin-Wessler) activity.
It is advantageously carried out at a pH ranging from 6 to 8, in particular close to neutral and at a temperature close to ambient. The heparinase is gradually added in the reaction mixture until hydrolysis is over.
The depolymerization with the heparinase may optionally be carried out on the fractions resulting from the oligosaccharidic fractions obtained after degradation of heparin with HNO2, or also on the oligosaccharides of higher molecular weight which are retained on immobilized AT III togetherwith the active oligosaccharides having less than 8 moieties and which are then eluted with these oligosaccharides having shorter chains.
The separation and the recovery of the fractions which contain the desired oligosaccharides is advantageously carried out by affinity chromatography in a column containing bound AT III.
Satisfactory results are obtained by using a gel of agarose such as the one commercialized under the trademark Sepharose, with ATIII molecules linked thereon.
To achieve the desired separation of the major part of the products contained in the depolymerization mixture and having a high anti-Xa activity, the column is advantageously equilibrated with a buffer having an ionic strength of about 0.2 M, preferably not less than 400.1 M, at a pH of 6 to 8, preferably close to or slightly higher than neutral.
The products devoid of or having a low affinity for AT III are eliminated by rinsing with a buffer advantageously of the same type as the one used for equilibrating the column.
A preferred embodiment for recovering the AT III retained or absorbed products, having an anti-Xa activity (Yin-Wessler) comprises desorbing and recovering all of the oligosaccharides by eluting them with a buffer having a sufficient ionic strength to that effect. The buffer used for the above mentioned elution is further advantageously selected among those which do not interfere with the subsequent recovery steps (particularly with alcohol precipitation) of the oligosaccharides contained in the recovered fractions. A buffer containing a calcium salt, such as calcium chloride that remains soluble in presence of an alcohol concentration (any suitable alcohol, for instance ethanol) which causes the precipitation of the oligosaccharides, is thus preferred.
A sodium salt can also be used.
After elution of the products having an AT III affinity, an alcoholic precipitation is advantageously carried out to recover them, their separation being then made for example by centrifugation.
In order to have oligosaccharidic fractions having the required high anti-Xa activity (Yin-Wessler) and a satisfactory homogeneity, the mixture of all the oligosaccharides previously retained on AT III is fractionated by a gel filtration or by ion exchange chromatography or both or by any other method which would yield similar results.
Advantageously, the last mentioned fractionation is so monitored that after the larger molecules have been eluted, the smaller ones are recovered, starting from those fractions which have a Yin-Wessler titer and a USP titer which are in a ratio of at least 30, preferably 100, the recovery extending to all the remaining fractions which still exhibit anti-Xa activity at least in the Yin-Wessler test.
Depending upon the amounts of solution subjected to gel filtration or chromatography, the volume of the successively eluted fractions will be selected as a matter of routine in order to select the most appropriate fractions with respect to the desired application.
Alternatively before the step of fixation on AT III, the oligosaccharides having more than 8 saccharidic moieties are eliminated from the depolymerization mixture, advantageously by gel filtration or a similar process as indicated above.
Biologically active octa-, hepta-, hexa-, penta-, tetra- and trisaccharides can be isolated from the eluted fractions obtained.
The pharmacological study of the fractions and oligosaccharides of the invention has shown a relationship between their anti-Xa activity as expressed in Yin-Wessler units and their antithrombotic activity.
Said fractions and oligosaccharides appear then capable of exerting a strong antithrombotic activity. Due to their low or nil global anticoagulant activity, the risks of hemorrhages are advantageously practically eliminated.
Among the assays made in vivo in order to study their antithrombotic activity, the following test has been carried out on the rabbit.
The formation of thrombus has been caused in the jugular vein of the rabbit by injecting a complex of activated prothrombin.
The ability of ABCDEFGH octasaccharide having a Yin-Wessler titer of 2000 units/mg to avoid the formation of the thrombus has been studied by injecting the octasaccharide before the injection of 25 units/kg of thrombogenic complex.
When injecting the oligosaccharides before the thromboplastin complex at doses of 150 to 250 iu/mg Yin-Wessler, a significant fraction is obtained with respect. to the formation of the thrombus.
Said octasaccharide appears then to have a strong antithrombotic activity. Advantageously, global anticoagulant activity is not detectable.
The oligosaccharide fractions according to the invention are free of toxicity. The administration of 10,000 U/kg (Yin-Wessler titer) of any of the fractions according to the invention causes in the rabbit neither any toxic reaction nor any pyrogenic effect in the pyrogenicity test in the rabbit according to the French Pharmacopea.
The compositions according to the invention are then particularly suitable for controlling specifically some steps of the coagulation in man or animal, more particularly when selective control of the activity of the blood factor Xa is desired (by way of example only, in patients, who are to undergo or who underwent surgery, in atheromatous diseases, perturbations of the coagulation mechanisms by bacterial or enzymatic activators, etc . . . )
The invention relates then to pharmaceutical preparations which contain oligosaccharidic fractions or the oligosaccharides themselves with high anti-Xa activity.
It relates more particularly to pharmaceutical preparation devoid of pyrogenic substances, containing an effective amount of active principles, in association with pharmaceutical excipients.
Particularly it concerns the compositions in which the pharmaceutical vehicle is suitable for the administration by oral route. Dosage forms of the invention suitable for the administration by oral route can advantageously be gastroresistant capsules, or tablets or pills.
Other pharmaceutical compositions include oligosaccharides or oligosaccharidic fractions in association with excipients suitable for the administration by rectal route. Corresponding dosage forms are suppositories.
Other dosage forms of the invention are sprays or ointments.
The invention also concerns pharmaceutical compositions which are injectable, sterile or sterilizable.
Such solutions advantageously contain 1,000 to 100,000 U (Yin-Wessler)ml of the oligosaccharidic fraction, preferably from 5,000 to 50,000 for example 25,000 U/ml, when these solutions are intended for subcutaneous injection or containing again, for example, from 500 to 10,000 for example, 5,000 units/ml of the oligosaccharidic fraction or oligosaccharide when they are intended for intravenous injection or for perfusion.
Advantageously, these pharmaceutical preparations are presented in the form of non-reusable syringes, ready for use at any suitable time.
The invention also concerns pharmaceutical compositions containing said oligosaccharides in association with another active principle, in particular useful for the prophylaxis and the treatment of thrombosis such as a veinotonic agent like dihydroergotamine, a salt of nicotinic acid or a thrombolytic agent like urokinase.
The oligosaccharidic fractions and oligosaccharides of the invention are advantageously in the form of a salt of at least one physiologically acceptable metal, such as sodium and/or calcium and/or magnesium.
The pharmaceutical compositions according to the invention are particularly adapted to the control (preventive or curative) of the blood coagulation in man or animal, notably in those cases where the host is subjected to risks of hypercoagulability, more particularly those resulting from the release by the organism of thromboplastin, for example, of tissular thromboplastin (surgical operations, atheromatous processes, tumor development, disturbances of the coagulation mechanisms by bacterial or enzymatic activators, etc . . . ). For the sole purpose of illustrating the invention, and without being a cause for limiting the protection of the invention, there will be indicated below, by way of example, a posology capable of being used in man: it comprises for example, the administration to the patient of 1,000 to 25,000 U by the sub-cutaneous route, 2 to 3 times daily, according to the level of hypercoagulation risk or the thrombotic condition of the patient, or from 1,000 to 25,000 U per 24 hours by the intravenous route, in discontinuous administration at regular intervals or continuously by perfusion, or again from 1,000 to 25,000 U (three times weekly) by the intramuscular route (titers expressed in Yin-Wessler U). The doses should naturally, be adjusted in each patient according to the results of previously effected blood analyses, the nature of the disorder from which the patient is suffering and, generally, his state of health, as is well known.
The invention also relates to the application of the oligosaccharides according to the invention for the preparation of a biological reactant usable in the laboratory, notably as a comparison reference for the study of other substances of which the anticoagulant activity is to be tested, notably at the level of inhibition of the factor Xa.
The description hereafter of examples of production of the oligosaccharides having YIN and WESSLER anticoagulant activity according to the invention will be given for the sake of further illustrating, yet in a nonlimitative manner, the invention.
Method for obtaining oligosaccharidic fractions including the steps of:
I. depolymerizing heparin with HNO2,
II. separating the biologically active oligosaccharides by chromatography on Sepharose-AT III,
III. gel filtration of the eluted fractions and recovery of the desired products.
20 g of heparin (USP titer: 150 UI/mg, YIN-WESSLER titer: 150 U/mg) were dissolved in 800 ml of water at room temperature. 200 ml of 0.5 M sulfuric acid and then 13.8 g of sodium nitrite were then added (final molarities of sulfuric acid: 0.1 M, and of the nitrite: 0.2 M). A reaction accompanied by the release of gaseous nitrogen was then produced. The reaction was stopped 15 minutes later by adjusting the pH at 7-7.2 with 5 N sodium hydroxide. The depolymerization products were precipitated by ethanol (7 volumes) that is, in this case, 7 liters. The precipitate was centrifuged, washed with alcohol and dried under vacuum.
______________________________________ Weight 24.8 g USP titer nil YIN-WESSLER titer 7 μ/mg ______________________________________
The apparent increase of weight of the precipitate was due to partial precipitation of sodium sulfate together with the depolymerization products.
The latter depolymerization products were then submitted to a chromatography on a SEPHAROSE gel comprising antithrombin III retained thereon. A column (diameter 2.6 cm, height 40 cm) containing 200 ml of SEPHAROSE-AT III (approximately 10 mg of immobilized bovin antithrombin III per ml of SEPHAROSE) was equilibrated with a buffer consisting of NaCl 0.2 M. tris-HCl 0.05 M pH 7.2.
1.6 g of the abovesaid depolymerization products were dissolved in 16 ml of 0.2 M NaCl buffer and percolated through a column at a flow-rate of 50 ml/h and the column was rinsed by 500 ml of 0.2 M NaCl buffer.
The retained oligosaccharides were then eluted from the column by a buffer capable of desorbing all of the oligosaccharides retained on the immobilized antithrombin III (CaCl2 0.2 M, tris-HCl 0.05 M, pH 7.2). The part of effluent which contained the oligosaccharides was recovered and the said oligosaccharides were precipitated by 10 volumes of ethanol.
After washing with ethanol and drying under vacuum, 5 mg of products are recovered having a USP titer of 66 UI/mg and a YIN and WESSLER titer of 1,600 U/mg.
The products so obtained consisted of a mixture of mucopolysaccharides of high molecular weight and of oligosaccharides of low molecular weight.
90 mg of a mixture of mucopolysaccharides and oligosaccharides obtained by a procedure of which the two preceding paragraphs are representative were dissolved in 2 ml distilled water, then deposited on the top of a column of the filtration gel formed of extremely fine particles commercialized under the denomination SEPHADEX G 50 (height 1 m, diameter 2.6 cm), equilibrated with distilled water. Development of the column with distilled water was carried out under a flow-rate of 24 ml/h. The effluent was recovered fraction-wise (6 ml per tube). The mucopolysaccharide content of each tube was evaluated by UV absorption at 206 nanometers.
The contents of the tubes were pooled to form the fractions numbered 1 to 5.
The mucopolysaccharides contained in each of these fractions were precipitated by alcohol and dried.
The weights and anticoagulant properties of these fractions were as follows:
______________________________________ fraction (1) weight 15 mg USP titer 156 μl/mg YIN-WESSLER titer 190 μ/mg fraction (2) weight 16 mg USP titer 139 μl/mg YIN-WESSLER titer 520 μ/mg fraction (3) weight 17 mg USP titer 50.3 μl/mg YIN-WESSLER titer 1 390 μ/mg fraction (4)weight 40 mg USP titer 7 μl/mg YIN-WESSLER titer 870 μ/mg fraction (5)weight 1 mg USP titer nil YIN-WESSLER titer 150 μ/mg ______________________________________
The ranges of molecular weights of the fractions so obtained, more particularly of the abovesaid "fraction 4" and "fraction 5" were appreciated both by paper chromatography and High Pressure Liquid Chromatography (HPLC) and on a comparative basis with the results obtained in the same experimental systems with a decasaccharide of heparin and:
in paper chromatography, with the reference products disclosed in the article of SILVA and DIETRICH (SILVA M. E. et DIETRICH C. P., J. Biol. chem. Vol. 250 (1975) pp. 6,841-6,846, and
in HPLC on a silica gel, with a series of polystyrene-sodium sulfonates of increasing known molecular weights and heparin samples of known molecular weights.
"Fraction 4" was found to consist of an oligosaccharide having less than 8 saccharide units and most likely not more than 6 saccharide units, and "fraction 5" of an oligosaccharide having less than 6 saccharides, most likely not more than 4 saccharide units.
Method for obtaining oligosaccharidic fractions including the steps of:
A.--depolymerizing heparin by digestion with an heparinase;
B.--fractionnating the depolymerization mixture by gel filtration on DEAE Sephadex A 25;
C.--selecting the biologically active products by chromatography on agarose AT III.
1. Preparation of the heparinase
Flavobacterium heparinum enzymes were used for degradating heparin.
The enzymes of flavobacterium heparinum were cultivated according to the method of Payza and Korn in J. Biol. Chem. 1956, 223, p. 853-858. The lyophilized cells were crushed under dry conditions in the presence of alumine and extracted by an acetate buffer at neutral pH.
The insoluble parts were eliminated and the solution was successively chromatographied on diethylaminoethyl cellulose and then on two agaroses such as those commercialized under the trademarks CM Sepharose CL 6B and Ultrogel ACA 54 respectively.
20 mg of heparinase having a degree of purity of 90% (the purity having been evaluated by electrophoresis) and a titer of 30,000 units/mg (8,333 units as measured by the method of HOVINGH et al (1970), J. Biol. Chem. 245 6, 1970) were thus obtained.
2. Depolymerization of heparin
1. g of heparin for use in therapy was dissolved in 50 ml of distilled water. 1 g of sodium acetate and 100 mg of calcium chloride were added thereto. The pH was adjusted to 7.2 by ClHO. 1 N.
1. mg of a solution of highly purified bacterial heparinase having a titre of 30,000 units/mg (8,333 units as measured by the method of HOVING et al (1970), J. Biol. Chem. 245, 6, 170) was added and the mixture was incubated for 15 hours at 30° C. After precipitation by 10 volumes of ethanol at 100° GL the depolymerized product obtained was dried. The product obtained was designated as P.
A column having a 16 mm diameter containing 50 ml of the gel known under the above commercial designation was equilibrated with a 0.1 M NaCl, pH 7.0 buffer. 20 ml of a solution of 180 mg of the above product P in said buffer were deposited on the top of the column and eluted with a gradient formed starting from 250 ml of a 0.1 M NaCl, pH 7.0 buffer, on the one hand, and of a 0.5 M CaCl2 pH 7.0 buffer, on the other hand. The flow rate was adjusted to 30 ml per hour. Successive 10 ml volumes were recovered.
The elution diagram (followed by optical density measurements at 232 nm) is represented on FIG. 1. The volumes were pooled into fractions 1, 2, 3, 4 according to the optical density measurements, as shown in FIG. 1. Their respective optical densities are shown in table 1 hereafter.
TABLE I ______________________________________ α!.sub.D .sup.b (c = 1, Yield in weight water No % On the DO..sub.H2O .sup.232 nm frac- from 120.8 mg of D band (conc: tion Weight starting product ofsodium 1 mg/ml ______________________________________ 1 22 mg 18% +33° 2.1 2 69 mg 57% +30° 3.2 3 20 mg 16% +30° 2.6 4 9.8 mg 8% +21° 1.7 ______________________________________
A column having a diameter of 2.5 cm containing 50 ml of agarose having AT III immobilized thereon (Agarose AT III) was equilibrated with 0.1 M. NaCl tris-HCl 0.025 M; pH 7.4.
60 mg of the fraction numbered 2 in table I (P 2) dissolved in 6 ml of the above buffer were deposited on the top of the column. Elution was carded out with successive solutions.
The first eluant used was the same as above: an effluent containing 50 mg of a product referred to as P 2 (B) contained in the first detected peak of optical density at 232 nm was separated therewith.
On changing the eluant to 0.2 M NaCl, 0.05 M tris HCl; pH 7.4, no active fraction was desorbed from the gel.
On further changing the eluant to 2 M CaCl2 a peak was obtained. The volumes containing the fractions which gave rise to said peak were precipitated by alcohol to provide 5 mg of a highly active fraction according to the invention (referred to as P 2(A).
The biological and physical characteristics of the last mentioned fraction are indicated herebelow:
______________________________________ YIN-WESSLER titer; 1 400 units/mg α!.sub.D .sup.20 = +24° (c = 1, water) DO..sub.HCl 0.03 N .sup.235 nm = 4.5 ______________________________________
The analytical results concerning P 2 (A) fraction are as follows:
1. Chemical analysis
The components of P 2 (A) were dosed as concerned:
the uronic acids, according to the method of Bitter T. et al. Anal. Biochem., 4, (1962), 330-334;
the hexosamines, on the one hand by the Elson-Morgan method, as modified by Antonopoulos C. A. et al., Biochem. Biophys. Acta 83, (1964), 1-19 (after hydrolysis of P 2 (A) by 6 N HCl for 4 hours, at 110° C. in a nitrogen atmosphere) and, on the other hand, by the method of Smith R. L. and Gilkerson E., Anal. Biochem., 98, (1979), 478-480, on samples of either non-hydrolysed, or hydrolysed samples of P 2 (A);
the sulfates, by the method of T. T. Terho et al., Anal. Biochem., 41, (1971), 471-476.
The results as to composition are summed up in table II hereafter, expressed as weight % (first line), as the mole to mole ratio with respect to the glucosamine units after hydrolysis (H+) according to the technique of Smith and Gilkerson (second line).
TABLE II ______________________________________ Hexosamines Smith-Gil. Uronic acids H.sup.(+) Antonopoulos Sulfates ______________________________________ P 2 (A) 15,2% 18,7% 12,8% 12% 0,9 1,0 0,7 1,4 ______________________________________
The results show that the oligosaccharides of the invention comprise substantially:
1. mole of uronic acid per 1 mole of hexosamine;
1.4 mole of sulfate per disaccharidic unit (including an uronic unit and an hexosamine unit);
2 N-sulfate-glusosamine units, per 1 N-acetylglusocamine units.
2 High Pressure Liquid Chromatography
50 μl of a solution of 0.5 mg/ml of P 2 (A) were subjected to an elution by 0.02 M Na2 SO4 (1 ml/minute) through a series of a first and second columns (250×4.6 cm) respectively filled with silica commercialized under the designation LICHROPHOSPHER Si 100, and a third column (250×3 cm) of the material commercialized (by WATERS and Associates) under the designation micro-BONDAGEL. The molecular weight of the fraction according to the invention was approximated by its time of elution (of of retention on the columns) with reference to the linear variations of the retention times of standard polystyrene-sulfonates of known molecular weights (of respectively 4,000, 6,500, 16,000 and 31,000) as well as of a tetrasaccharide having a known molecular weight of 700-900 subjected to the same assays, as a function of the logarithm values corresponding to said molecular weights. The measurements were made using a SPECTRAPHYSICS 3500 chromatograph, and the detection of the fraction by UV spectrophotometry (200 mμ and 230 mμ).
This assay, as well as an other chemical assay according to the method A. Linker and P. Hovingh, Biochem. vol. 11, No. 4, 1972, p. 563-567, confirmed the fact that the active oligosaccharide contains not more, and even less than 8 saccharidic units.
3. Ultra-violet absorption
UV-absorption was carried out on a solution of 100 γ/ml of P 2 (A) and in an UV band of 215-260 nm. Maximum absorption was observed in the 230-235 nm band.
Method for obtaining oligosaccharidic fractions including the steps of:
I. enzymatic depolymerization of heparin;
II. selecting the biologically active products by chromatography on Sepharose AT III;
III. gel filtration of the eluted fractions and recovery of the desired products.
20 mg of heparin for use in therapy were dissolved in 100 ml of an acetate buffer (NaOAc 0.15 M, NaCl 0.15 M; Ca Cl2 0.005 M; pH 6.9).
The solution was incubated for 24 hours at 30° C.
The highly purified heparinase previously obtained was added to the solution as follows:
0.4 mg (amount based on the dosage of the proteins) at the time t=0,
0.2 mg at the time t=+8 hours,
0.2 mg at the time t=+24 hours
At t=+36 hours, another addition of heparinase did not cause an increase of the optical density at 232 nm. The reaction was considered as ended and the products were recovered by alcoholic precipitation and were dried (yield in weight 90%).
A chromatography column (5×18 cm) containing 10 mg of bound AT III/ml of Sepharose was equilibrated with 0.1. M Na Cl; tris-HCl 0.05 M; pH 7.5. 2 g of the products of degradation of heparin were deposited on the top of the column. The column was rinsed with said buffer whereby the unfixed fractions were eliminated (the corresponding products being designated as UP hereinafter). The fixed products (designated as F P-were then eluted with a solution of CaCl2 1 M pH 7.2. The products were precipitated with alcohol and recovered by centrifugation. 1.6 g UP on the one hand and 8 mg of FP having 800 ui/mg (Yin-Wessler), on the other hand are thus recovered.
UP and FP products were subjected separately to gel filtration 25 mg of each product were filtrated on a column. (200×0.6 cm) of a Sephadex G 50 Superfine gel. The elution was carried out using a solution of NaCl 0.2 M Fractions of 0.65 ml were collected. After elimination of the salts on Sephadex G 25, the products were lyophilized, FIG. . .3.!. .Iadd.2 .Iaddend.represents the elution diagrams of UP fractions (continuous line) and FP (fractions (dotted line). The elution has been controlled by optical density measurements at 230 nm (absorption wavelength of the double bond created by the heparinase).
According to the optical density measurements, UP fraction was fractionated into di-, tetra-, hexa- and octasaccharides (UP2, UP4, UP6 and UP8) and into another product having a higher polymerization degree (UP+8). UP8 and UP+8 do not appear on the elution curve of FIG. 2 as they only represent a very low percentage (3.4 and 1.3% respectively) and are only detected at high sensitivity. FP fraction was separated into four fractions designated FPa,b,c and d, according to the order of the decreasing elution volume. The major part of FP fractions is eluted slightly before UP fraction.
Results concerning each of UP and FP fractions are given in the table hereinafter.
They comprise: the elution volume (ml) of each of said fractions, issued from UP and FP fractions; the % of each of them in the mixture of the UP and FP fractions respectively, the specific rotatory power of each fraction (measured with an electronic polarimeter in aqueous solutions usually 1%); the absorbance at 230 mn (measured in a 0.01% solution in HCl 0.03 M, the results being expressed as optical density of 1% solution); and the anti-Xa activity in human plasma of FP fractions measured according to the test of Yin and Wessler above mentioned.
TABLE __________________________________________________________________________ Elution Volume % in the α!.sub.D .sup.20 (c = 1, water) Activity anti-Xa Fraction (ml) mixture on the D band of sodium DO..sub.H2O .sup.230 nm μl/mg Yin-Wessler __________________________________________________________________________UP 2 52-60 52 +5 6 -- UP 4 47-52 30,5 +23,5 4,8 --UP 6 43-47 13 +37 3,3 -- UP 8 40-43 3,4 +41,5 2,5 -- UP + 8 37-40 1,3 2 FPa 40-45 50 +39 3,2 1200(2000 in another te) FPb 35-39 23 +41 2,5 930 FPc 27-34 14 -- -- 200 FPd 23-26 5 -- -- 330 __________________________________________________________________________
It appears from the results given in the table that each of the FPa fractions exibit an anticoagulant activity, FPA having the most important biological activity. It will be noted that it represents 50 to 75% of the FP mixture. The FPa fraction was submitted to various treatments in order to elucidate its structure. The following analytical results were obtained.
The FPa fractions recovered after the gel filtration were incubated with HNO2 in an aqueous medium under conditions enabling degradation of the oligosaccharidic chains. The degradation was carried out according to the method of Shiveley and Conrad in Biochemistry 1976, 15, p. 3932-3942.
Under the action of NHO2 the oligosaccharidic chains are fragmented into di- and tetrasaccharides, the break taking place behind the N-sulfated glucosamine moieties said moieties being converted into 2,5 anhydromannose groups.
The di- and tetrasaccharides so obtained are separated by chromatography of Sephadex G50 (200×0.5 cm; NaCl 0.2 M.) The elution diagram is given on FIG. 3.
The following measurements are made on each fraction: the optical density at 230 nm (curve a) the amount of uronic acids (curve b) of 2,5-anhydro-mannose (curve c) and of glucosamine (before and after acid hydrolysis), the radio activity when the analysed products have been tritiated before being degradated by HNO2.
The optical density measurement of these fractions shows that the major part of the unsaturated molecules are disaccharides, 90% or the optical density being in the peak of the disaccharide while 10% are in the peak of the tetrasaccharidic fragment.
It can be considered therefrom that the tetrasaccharidic unit does not contain an uronic acid moiety with a double bond. Such moiety is part of a disaccharide which contains further an N-sulfoglucosamine, this disaccharide GH is located at the non reducing end of the oligosaccharide before its nitrous degradation.
Besides, by dosing 2,5 anhydro-mannose groups in these fractions (curve c in FIG. 3), 33% of 2,5 anhydromannose groups are found in the tetrasaccharidic fragments and 66% in the disaccharidic fragments. By assuming that the oligosaccharidic chains are N-sulfoglucosamine terminated, it can be concluded from said results that FPa contains two disaccharidic chains for one tetrasaccharidic chain (see curve b on FIG. 3). Said results were confirmed by the dosage of the uronic acids (curve b) according to Bitter and Muir in Annal; Biochem. 1962,4 p. 330-334 and of the glucosamine moieties in the degradated products originating from FPA, i.e. said degradated products comprise twice as many disaccharidic molecules as tetrasaccharidic melocules.
By reducing FPa before the nitrous degradation, the reducing ends of the chains are not converted into 2,5-anhydro-mannose during the nitrous degradation. The reduction is carried out with a sodium borohydride buffer at pH 9.5. The reducing ends of the FPa oligosaccharidic chains are then converted into tritiated hexitols. The reduced product is separated from the salts present in the mixture by filtration on Sephadex G 25. It is then submitted to nitrous acid degradation and gel filtration as described above. The dosage of 2,5-anhydro-mannose groups is then carried out and shows a clear decrease of said groups in the disaccharidic fraction while the tetrasaccharidic fractions remain practically unchanged.
By reducing with tritiated borohydride, 70 to 80% of the radioactivity are found in the disaccharides and 20 to 30% in the tetrasaccharides. Furthermore, it was observed that after said treatment, the amount of 2,5-anhydro-mannose decreases far more in the disaccharidic peak than in the tetrasaccharidic peak--such result being in favour of the presence of a disaccharidic fragment at the reducing end (70% of the molecules) and also of a tetrasaccharide (30%).
The FPa fraction was further submitted to a nitrous acid degradation under very mild conditions. It was thus possible to obtain, after gel filtration and affinity chromatography an oligosaccharide fraction containing mainly the two hexasaccharides with ABCDEF and CDEFGH sequences the latest being also part of the invention.
The procedure involved treatment of the said FPa fraction with nitrous acid as described by Cifonelli and King (Carbohydrate Res. 1972, 21,pp. 173-186), except that the reaction was stopped between 1 and 5 mn and preferably 3 mn. The fragments thus obtained were desalted by gel filtration on Sephadex G 25 and submitted to an affinity chromatography in the same conditions as described above.
Two main species, i.e. CDEFGH and ABCDEF were found in the eluted fractions, as shown by the analytical methods described above for study of the FPa fraction. They still had a high anti-Xa activity (Yin and Wessler).
The octasaccharidic fraction was isolated. It presented a YW titer of 2000 IU/mg and an APTT titer of 4 IU/mg. The 13 C NMR spectrum of this product was recorded (see FIG. 5). If confirms that the product is an octasaccharide. It also confirms the assigned structure (ABCDEFGH sequence). The signals observed are respectively characteristic of the:
anomeric carbon in position 1 (90-105 ppm) of the various moieties (A,B,C,D,E,F,G and H) of the structure (the corresponding moiety being mentioned for each peak to enable their identification); on the figure
carbons in position 6 (about 60 and about 70 ppm) (signal C6) and in position 2 (55-60 ppm) (signal C2) of the glucosamine moieties;
CH3 of --NHAc group in D (about 25 ppm). Furthermore the presence of a new resonance signal in the C-2 region of N-sulfo-amino-glucosamine residue is observed (signal x--this signal does not correspond to any resonance signal in NMR spectra obtained under similar conditions with a conventional heparin).
In another set of experiments, the mixture obtained after the affinity chromatography step (81 mg), was chromatographied on a column (200×2.5 cm) of Sephadex G-50 superfine gel.
The elution was performed with 0.2 M sodium chloride. The products were detected by U.V absorption at 232 nm (see FIG. 4).
The major part of the product was eluted in the octasaccharidic region, and presented the same properties as the product previously described.
The hexasaccharide fraction was collected and the salts were eliminated. The product thus obtained was freeze-dried. Then yield was 2 mg.
This compound was highly active in the YW test: 510 IU/mg. Its APTT titer was 3IU/mg. Since this hexasaccharidic fraction is obtained after heparinase degradation, it contains the residues A and H characterized in the octasaccharidic fraction. Moreover, since this product presents affinity for ATIII it should contain a CDEF tetrasaccharidic sequence. Thus it can be represented by ABCDEF structure.
However one cannot exclude the presence, in this material, of small amount of a product having CDEFGH structure, where C is an unsaturated hexuronic acid residue (the 2-OH group being sulfated or not).
A study carried out as described for the octasaccharide (i.e. nitrous acid degradation and examination of the fragments) indicates the presence of both ABCDEF and CDEFGH.
1--By using the method described by L. A. Fransson in Carbohydrate Research 62,235-244, 1978 ABCDEFGH octasaccharide is submitted to an oxidation reaction with sodium periodate in phosphate medium, pH 7 at 37° C. during about 14 hours. An alkaline hydrolysis is caused by adding NaOH to a pH of 11-12 and the reaction mixture is allowed to stay at room temperature for 30 minutes. It is then neutralized; a trisaccharide which is likely to have a structure FGH is separated by chromatography on Sephadex G 50. The determination of the anti-Xa activity according to the Yin-Wessler test give a value about 100-200 ui/mg depending on the assay.
2--Said octasaccharide is submitted to the action of a purified heparitinase, extracted from Flavobacterium heparinum. The experimental conditions (in particular, pH, temperature, time) correspond to those used in the enzymatic degradation according to example 2. Two tetrasaccharides to which structures EFGH and ABCD can be given are recovered by filtration on SEPHADEX G 50 (carried out as in example 2). By passing the tetrasaccharides through a column of Sepharose ATIII, EFGH is be retained while ABCD is eliminated. EFGH is then recovered by elution with a solution NaCl 1 M. The Yin-Wessler activity, measured in various assays, is about 100-200 ui/mg.
3--Octasaccharide ABCDEFGH is submitted to a mild nitrous degradation. 1 mg of octasaccharide is used per ml of solution--HNO2 is generated in situ by adding NaNO2 N/1000 and Hcl. The pH is adjusted to 3. After 10 mn, at the ambient, the pH is adjusted to 7. The reaction mixture is submitted to a gel filtration followed by an affinity chromatography, using the conditions disclosed in the preceeding examples. By elating with NaCl 1 M or CaCl2 1 M, a product can be recovered having presumably hexasaccharidic structure CDEFGH. Said product is submitted to the action of an iduronidase extracted from human kidney. The enzymatic degradation step is carried out at pH 7 at 37° C.
An oligosaccharide to which pentasaccharidic structure DEFGH is attributed is obtained by filtration of the depolymerization mixture on Sephadex G 50. The anti-Xa (Yin-Wessler) activity of this product appears to be over 400 ui/mg.
The 13 C NMR spectrum of this fraction shows the presence of said signal * in the region of C-2 of glucosamine residues (see FIG. 6). This signal can be assigned to a glucosamine unit which is N-sulfated and substituted by a --OSO3 - group in position 3.
This glucosamine unit is sulfated or not in position 6.
Furthermore, the integral curve confirms that the product has an average number of moieties of less than 8 and comprises a major part of hexasaccharidic and octasaccharidic species. Starting from beef lung heparin, after controlled degradation, followed by affinity chromatography and gel filtration as described above an octasaccharide having the structure ABCFGHGH can be isolated. This product was highly active in an anti-Xa assay. An hexasaccharide ABCFGH was also extracted in minute amount. Ic was also active in an anti-Xa assay.
The invention extends of course to the oligosaccharides that may be obtained by other depolymerization techniques of heparin or heparinic compounds followed by the subsequent recovery of the oligosaccharides of low molecular weight having anticoagulant activity as measurable by the YIN-WESSLER test.
As an example of another depolymerization technique of heparin or related compounds, one may cite periodic oxidation. One may also cite the technique which consists in producing an α,β elimination reaction by chemical means on heparin or esters of heparin giving similar results, or the process which comprises:
contacting the starting heparin fraction with antithrombin III immobilized on a Sepharose gel to fix the antithrombin-binding components of said heparin fraction,
digesting the so fixed heparin with a bacterial heparinase and
eluting the antithrombin-binding fragments from the gel whereby an eluant containing the above said fragments, all of which may then be subjected to the further steps of the above-defined process.
Claims (16)
1. An oligosaccharide fraction of the heparin chain which oligosaccharide has improved antithrombotic activity in vivo higher than that of heparin (as measured by the Yin-Wessler test), which oligosaccharide fraction (1) comprises not more than 8 saccharide units, (2) of which one is an N-sulfate-3-O-sulfate-D-glucosamine unit (3) has anti-Xa activity at least 10 times that of heparin, (4) specific affinity for AT III, (5) a ratio of Yin-Wessler titer to USP titer of at least 30 and (6) virtually no anticoagulant activity (as determined by the USP test) and, the biologically acceptable salts of said oligosaccharide.
2. The oligosaccharide of claim 1 which oligosaccharide contains a saccharide sequence of units selected from the group consisting of ABCDEFGH, ABGHCDEF, ABCDEF, CDEFGH and DEFGH, wherein A, B, C, D, E, F, G and H are defined as follows
A=unsaturated or saturated uronic acid
B=N-sulfate-D-Glucosamine or N-sulfate-6-O-sulfate-D-glucosamine
C=L-iduronic acid or, where present at a chain end, unsaturated uronic acid
D=N-acetyl-D-glucosamine or N-acetyl-6-O-sulfate-D-glucosamine
E=D-glucuronic acid
F=N-sulfate-3-O-sulfate-D-glucosamine or N-sulfate-3-O-sulfate-6-O-sulfate-D-glucosamine
G=2-O-sulfate-L-iduronic acid, and
H=N-sulfate-D-glucosamine or N-sulfate-6-O-sulfate-D-glucosamine.
3. The oligosaccharide of claim 1 wherein the N-sulfate-D-glucosamine is N-sulfate-3-O-sulfate-6-O-sulfate-D-glucosamine.
4. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of N-acetyl-D-glucosamine, D-glucuronic acid, 2-O-sulfate-L-iduronic acid or N-sulfate-D-glucosamine.
5. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of 2-O-sulfate-4,5 unsaturated uronic acid, N-sulfate-D-glucosamine or L-iduronic acid.
6. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of N-sulfate-6-O-sulfate-D-glucosamine, L-iduronic acid, 2-O-sulfate-L-iduronic acid or N-sulfate-D-glucosamine.
7. The oligosaccharide of claim 2 wherein the saccharide sequence is selected from the group consisting of CDEFGH or ABCDEF.
8. The oligosaccharide of claim 2 wherein the saccharide sequence is selected from the group consisting of DEFGH.
9. The oligosaccharide of claim 1 which is the sodium, calcium or magnesium salt.
10. The oligosaccharide of claim 1 wherein the N-sulfate-D-glucosamine unit is at the reducing end of the oligosaccharide chain.
11. The oligosaccharide of claim 1 which comprises one N-acetyl-glucosamine saccharide moiety for every two or three N-sulfate-glucosamine saccharide moieties.
12. A therapeutic antithrombotic composition which has antithrombotic activity higher than that of heparin (as measured by the Yin-Wessler test) which composition comprises a therapeutically acceptable carrier and in a therapeutically effective amount, an oligosaccharide of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11.
13. The therapeutic composition of claim 12 in which the ratio of Yin-Wessler titer to USP titer is at least about 100.
14. The therapeutic composition of claim 12 in which the oligosaccharide has a Yin-Wessler titer of 100 to about 2,000 U/mg.
15. A therapeutic method for controlling thrombosis in a patient which comprises administering to said patient the therapeutic antithrombotic composition of claim 12 and controlling thrombosis.
16. The therapeutic method of claim 15 in which the administration of the composition is at periodic intervals.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/574,761 USRE35770E (en) | 1978-11-06 | 1995-12-19 | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them |
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7831357A FR2440376A1 (en) | 1978-11-06 | 1978-11-06 | MUCOPOLYSACCHARIDIC COMPOSITION HAVING REGULATORY COAGULATION ACTIVITY, MEDICAMENT CONTAINING SAME AND METHOD FOR OBTAINING SAME |
FR7831357 | 1978-11-06 | ||
FR7918873 | 1979-07-20 | ||
FR7918873A FR2461719A2 (en) | 1979-07-20 | 1979-07-20 | Anticoagulant heparin muco:polysaccharide fraction - with improved specificity produced by alcohol fractionation of heparin |
GB7934673 | 1979-10-05 | ||
GB7934673 | 1979-10-05 | ||
US9116479A | 1979-11-05 | 1979-11-05 | |
GB8000443 | 1980-01-07 | ||
GB8000443 | 1980-01-07 | ||
GB8021749 | 1980-07-02 | ||
GB8021750 | 1980-07-02 | ||
GB8021749 | 1980-07-02 | ||
GB8021750 | 1980-07-02 | ||
GB8029697 | 1980-09-15 | ||
GB8029697 | 1980-09-15 | ||
US06/194,545 US4401662A (en) | 1979-10-05 | 1980-10-06 | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them |
US08/574,761 USRE35770E (en) | 1978-11-06 | 1995-12-19 | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US9116479A Continuation-In-Part | 1978-11-06 | 1979-11-05 | |
US06/194,545 Reissue US4401662A (en) | 1978-11-06 | 1980-10-06 | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE35770E true USRE35770E (en) | 1998-04-14 |
Family
ID=27576212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/574,761 Expired - Lifetime USRE35770E (en) | 1978-11-06 | 1995-12-19 | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE35770E (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
US20030124652A1 (en) * | 2001-12-21 | 2003-07-03 | Novazyme Pharmaceuticals, Inc. | Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells |
US20030143669A1 (en) * | 2001-12-21 | 2003-07-31 | Novazyme Pharmaceuticals, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester alpha-N-acetyl glucosimanidase |
US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
US20040171819A1 (en) * | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20050090561A1 (en) * | 2003-07-24 | 2005-04-28 | Volker Laux | Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them |
US20050171055A1 (en) * | 2000-07-21 | 2005-08-04 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20050170449A1 (en) * | 2001-12-21 | 2005-08-04 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US20110201801A1 (en) * | 2008-05-30 | 2011-08-18 | Momenta Pharamaceuticals, Inc. | Saccharide structures and methods of making and using such structures |
US20220362283A1 (en) * | 2021-05-12 | 2022-11-17 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
US11542534B2 (en) | 2019-07-09 | 2023-01-03 | Optimvia, Llc | Methods for synthesizing anticoagulant polysaccharides |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3506642A (en) * | 1967-07-03 | 1970-04-14 | Canada Packers Ltd | Stable orally active heparinoid complexes |
US3985871A (en) * | 1974-04-04 | 1976-10-12 | Crinos Industria Farmacobiologica S.P.A. | Pharmaceutical heparinoidic factor-containing composition and therapeutic use thereof |
US4122250A (en) * | 1977-08-22 | 1978-10-24 | Gottfried Schmer | Separation of high-activity heparin by affinity chromatography |
GB2002406A (en) * | 1977-08-09 | 1979-02-21 | Hepar Chimie Sa | Oligoheteropolysaccharides having a heparin-like activity method for their preparation and pharmaceutical compositions based thereon |
US4175182A (en) * | 1978-07-03 | 1979-11-20 | Research Corporation | Separation of high-activity heparin by affinity chromatography on supported protamine |
US4213962A (en) * | 1977-07-27 | 1980-07-22 | Yoshiharu Miura | Artificial medical material with anticoagulative activity |
US4281108A (en) * | 1980-01-28 | 1981-07-28 | Hepar Industries, Inc. | Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained |
-
1995
- 1995-12-19 US US08/574,761 patent/USRE35770E/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3506642A (en) * | 1967-07-03 | 1970-04-14 | Canada Packers Ltd | Stable orally active heparinoid complexes |
US3985871A (en) * | 1974-04-04 | 1976-10-12 | Crinos Industria Farmacobiologica S.P.A. | Pharmaceutical heparinoidic factor-containing composition and therapeutic use thereof |
US4213962A (en) * | 1977-07-27 | 1980-07-22 | Yoshiharu Miura | Artificial medical material with anticoagulative activity |
GB2002406A (en) * | 1977-08-09 | 1979-02-21 | Hepar Chimie Sa | Oligoheteropolysaccharides having a heparin-like activity method for their preparation and pharmaceutical compositions based thereon |
US4122250A (en) * | 1977-08-22 | 1978-10-24 | Gottfried Schmer | Separation of high-activity heparin by affinity chromatography |
US4175182A (en) * | 1978-07-03 | 1979-11-20 | Research Corporation | Separation of high-activity heparin by affinity chromatography on supported protamine |
US4281108A (en) * | 1980-01-28 | 1981-07-28 | Hepar Industries, Inc. | Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained |
Non-Patent Citations (2)
Title |
---|
Choay et al. Thrombosis Research 1980, 18(3/4), 573 578. * |
Choay et al. Thrombosis Research 1980, 18(3/4), 573-578. |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089869A1 (en) * | 1999-09-14 | 2005-04-28 | Genzyme Glycobiology Research | GlcNac phosphotransferase of the lysosomal targeting pathway |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
US20060073498A1 (en) * | 1999-09-14 | 2006-04-06 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
US6670165B2 (en) | 1999-09-14 | 2003-12-30 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
US6828135B2 (en) | 1999-09-14 | 2004-12-07 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester α-GlcNAcase of the lysosomal targeting pathway |
US6969705B2 (en) | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20050171055A1 (en) * | 2000-07-21 | 2005-08-04 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US7812007B2 (en) | 2000-07-21 | 2010-10-12 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20030143669A1 (en) * | 2001-12-21 | 2003-07-31 | Novazyme Pharmaceuticals, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester alpha-N-acetyl glucosimanidase |
US20050003486A1 (en) * | 2001-12-21 | 2005-01-06 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester alpha-N-acetyl glucosimanidase |
US6800472B2 (en) | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
US20050170449A1 (en) * | 2001-12-21 | 2005-08-04 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US20030124652A1 (en) * | 2001-12-21 | 2003-07-03 | Novazyme Pharmaceuticals, Inc. | Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells |
US20040171819A1 (en) * | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
US20080182820A1 (en) * | 2002-10-10 | 2008-07-31 | Christian Viskov | Mixtures of sulfated oligosaccharides |
US8003623B2 (en) | 2002-10-10 | 2011-08-23 | Aventis Pharma S.A. | Mixtures of sulfated oligosaccharides |
US20050090561A1 (en) * | 2003-07-24 | 2005-04-28 | Volker Laux | Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them |
US7956046B2 (en) | 2003-07-24 | 2011-06-07 | Aventis Pharma S.A. | Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them |
US20110201801A1 (en) * | 2008-05-30 | 2011-08-18 | Momenta Pharamaceuticals, Inc. | Saccharide structures and methods of making and using such structures |
US8614314B2 (en) | 2008-05-30 | 2013-12-24 | Momenta Pharmaceuticals, Inc. | Saccharide structures and methods of making and using such structures |
US9163047B2 (en) | 2008-05-30 | 2015-10-20 | Momenta Pharmaceuticals, Inc. | Saccharide structures and methods of making and using such structures |
US11542534B2 (en) | 2019-07-09 | 2023-01-03 | Optimvia, Llc | Methods for synthesizing anticoagulant polysaccharides |
US20220362283A1 (en) * | 2021-05-12 | 2022-11-17 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
US11712447B2 (en) * | 2021-05-12 | 2023-08-01 | NexEos Diagnostics, Inc. | Methods of manufacturing a high molecular weight heparin compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4401662A (en) | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them | |
US5013724A (en) | Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications | |
US4496550A (en) | Oligosaccharides having selective anticoagulation activity | |
EP0014184B2 (en) | Heparin fragments having a selective anticoagulation activity and process for their preparation | |
US4990502A (en) | Low molecular weight heparins of regular structure, their preparation and their biological uses. | |
US4826827A (en) | Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs | |
Hook et al. | Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin | |
US4847338A (en) | Low molecular weight heparin fragments as inhibitors of complement activation | |
US5039529A (en) | Novel heparin derivatives | |
Linhardt et al. | Structure and activity of a unique heparin-derived hexasaccharide. | |
IL98604A (en) | Heterogeneous admixture of heparinic polysaccharides their preparation and pharmaceutical compositions containing them | |
US4804652A (en) | Mucopolysaccharides having biological properties, preparation and application thereof as drugs | |
NZ197081A (en) | Mixtures of sulphated polysaccharides | |
Linker et al. | Structural studies on heparin. Tetrasaccharides obtained by heparinase degradation | |
WO1990001501A1 (en) | Oligosaccharide heparin fragments as inhibitors of complement cascade | |
US4486420A (en) | Mucopolysaccharide composition having a regulatory action on coagulation, medicament process for preparation and method of use | |
USRE35770E (en) | Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them | |
CA1180292A (en) | Short chain oligosaccharides possessing biological properties, their preparation and their use as medicaments | |
AU671817B2 (en) | Sulphated polysaccharides, preparation thereof, pharmaceutical composition and use thereof | |
Linhardt et al. | New methodologies in heparin structure analysis and the generation of LMW heparins | |
AU2004259111B2 (en) | Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures | |
WO1992018546A1 (en) | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation | |
EP0408770A1 (en) | New sulfated polysaccharide, pharmaceutically acceptable salts thereof, preparation thereof, and drug containing the same as active ingredient | |
WO1994029352A1 (en) | Polysaccharides having high antithrombotic and anticoagulant activity |